Wet AMD (The Anti-VEGF Era and Beyond in Wet AMD: The Impact of Clinical Attributes and Market Access Status on Current and Future Prescribing Decisions Among Retinal Specialists) | Physician & Payer Forum | EU5 | 2014

Treatment for the wet (exudative, neovascular) form of age-related macular degeneration (AMD) in Europe is characterized by several current therapies targeting vascular endothelial growth factor (VEGF). Notable agents, administered via intravitreal (eye) injections, include Lucentis (Novartis), Eylea (Bayer), and compounded Avastin (Roche/Genentech/Chugai). However, the cost-constrained European health authorities are increasingly questioning the value of these agents, especially when compared with the VEGF inhibitor Avastin, which does not have marketing approval for the treatment of wet AMD, but which is priced significantly lower than Lucentis or Eylea. Because emerging agents offering novel mechanisms of action, greater convenience, or enhanced efficacy through adjunctive therapy are expected to launch in coming years, this report examines levers to optimize market access in the EU5 (France, Germany, Italy, Spain, United Kingdom).

Contact sales account_box

Report

Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)

Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…

north_east

Report

Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)

Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…

north_east

Report

Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)

Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…

north_east

Report

Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)

Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…

north_east

Report

Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)

Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…

north_east

Product logins

Wet AMD (The Anti-VEGF Era and Beyond in Wet AMD: The Impact of Clinical Attributes and Market Access Status on Current and Future Prescribing Decisions Among Retinal Specialists) | Physician & Payer Forum | EU5 | 2014

Related Market Assessment Reports

Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)

Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)

Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)

Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)

Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)

Follow us

Contact us